SAN DIEGO, May 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.
Details of the presentations are as follow:
Event: | BofA Securities 2023 Health Care Conference | |||
Format: | Corporate Presentation and 1x1 Meetings | |||
Presentation Date: | Wednesday, May 10, 2023 | |||
Presentation Time: | 4:20 p.m. PT / 7:20 p.m. ET | |||
Location: | Las Vegas, NV | |||
Event: | JMP Securities Life Sciences Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Monday, May 15, 2023 | |||
Presentation Time: | 10:30 a.m. PT / 1:30 p.m. ET | |||
Location: | New York, NY | |||
Event: |
Benchmark Healthcare House Call Investor Conference | |||
Format: | 1x1 Meetings | |||
Date: | Tuesday, May 23, 2023 | |||
Location: | Virtual |
A live audio webcast of the BofA and JMP Securities presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcast will be available for 90 days following the conference.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO® and NOCDURNA® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Pfizer and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
SOURCE Halozyme Therapeutics, Inc.